We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

38 hedge funds and large institutions have $66.5M invested in Aldeyra Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

9% more funds holding

Funds holding: 35 → 38 (+3)

1.94% more ownership

Funds ownership: 49.2% → 51.14% (+1.9%)

0% more capital invested

Capital invested by funds: $66.4M → $66.5M (+$95K)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
13
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.5M
2
Millennium Management
Millennium Management
New York
+$1.12M
3
MP
Mangrove Partners
Connecticut
+$1.08M
4
6CM
683 Capital Management
New York
+$524K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$335K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$375K
2
TSS
Two Sigma Securities
New York
-$365K
3
EMG
Ellington Management Group
Connecticut
-$168K
4
Squarepoint
Squarepoint
New York
-$159K
5
Renaissance Technologies
Renaissance Technologies
New York
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$21M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$11M – – –
SFM
3
Sphera Funds Management
Israel
$7.1M – – –
6CM
4
683 Capital Management
New York
$6.22M +$524K +79,486 +10%
Millennium Management
5
Millennium Management
New York
$4.87M +$1.12M +170,594 +31%
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.75M +$1.5M +227,503 +48%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$4.71M -$375K -57,000 -8%
MP
8
Mangrove Partners
Connecticut
$1.12M +$1.08M +164,384 New
KCM
9
Knoll Capital Management
Florida
$844K – – –
HP
10
Hikari Power
Japan
$733K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$695K +$173K +26,269 +35%
Renaissance Technologies
12
Renaissance Technologies
New York
$422K -$152K -23,100 -27%
WC
13
Woodstock Corp
Massachusetts
$396K +$64.9K +9,850 +20%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$346K +$335K +50,923 New
WMSA
15
Weiss Multi-Strategy Advisers
New York
$340K – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$338K +$327K +49,676 New
AAP
17
Ardsley Advisory Partners
Connecticut
$306K +$35.9K +5,448 +14%
BlackRock
18
BlackRock
New York
$256K +$178 +27 +0.1%
Northern Trust
19
Northern Trust
Illinois
$244K +$122K +18,594 +108%
State Street
20
State Street
Massachusetts
$155K +$27.5K +4,169 +23%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$125K -$1.26K -192 -1%
HighTower Advisors
22
HighTower Advisors
Illinois
$111K -$88.3K -13,400 -45%
OAM
23
Oxford Asset Management
United Kingdom
$95K +$94.1K +14,287 New
Wells Fargo
24
Wells Fargo
California
$92K +$89.2K +13,540 New
DS
25
DRW Securities
Illinois
$82K – – –
1
2

ALDX Hedge Fund Activity: Q4 2017 in Review

38 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2017, worth a combined $66.5M — up 0.14% from $66.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ALDX positions and 6 closed out — a net gain of 3 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.5M. The largest seller was Adage Capital Partners, cutting an estimated $375K.

  • 38 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2017, up from 35 in Q3 2017.
  • Funds reported $66.5M of Aldeyra Therapeutics stock for Q4 2017, up 0.14% quarter-over-quarter.
  • 9 funds opened new Aldeyra Therapeutics positions in Q4 2017 and 6 closed out, a net change of +3 holders.
  • The largest Aldeyra Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $1.5M added.
  • The largest Aldeyra Therapeutics seller in Q4 2017 was Adage Capital Partners, an estimated $375K sold.

Based on aggregated 13F filings for Q4 2017.